Innovative Bioconjugation Technology for Antibody–Drug Conjugates: Proof of Concept in a CD30-Positive Lymphoma Mouse Model
- 25 February 2021
- journal article
- research article
- Published by American Chemical Society (ACS) in Bioconjugate Chemistry
- Vol. 32 (3) , 595-606
Abstract
To overcome stability and heterogeneity issues of antibody–drug conjugates (ADCs) produced with existing bioconjugation technologies incorporating a maleimide motif, we developed McSAF Inside, a new technology based on a trifunctionalized di(bromomethyl)pyridine scaffold. Our solution allows the conjugation of a linker-payload to previously reduced interchain cysteines of a native antibody, resulting in disulfide rebridging. This leads to highly stable and homogeneous ADCs with control over the drug-to-antibody ratio (DAR) and the linker-payload position. Using our technology, we synthesized an ADC, MF-BTX-MMAE, built from anti-CD30 antibody cAC10 (brentuximab), and compared it to Adcetris, the first line treatment against CD30-positive lymphoma, in a CD30-positive lymphoma model. MF-BTX-MMAE displayed improved DAR homogeneity, with a solid batch-to-batch reproducibility, as well as enhanced stability in thermal stress conditions or in the presence of a free thiol-containing protein, such as human serum albumin (HSA). MF-BTX-MMAE showed antigen-binding, in vitro cytotoxicity, in vivo efficacy, and tolerability similar to Adcetris. Therefore, in accordance with current regulatory expectations for the development of new ADCs, McSAF Inside technology gives access to relevant ADCs with improved characteristics and stability.Keywords
Funding Information
- Association Nationale de la Recherche et de la Technologie (2017/0516)
- Region Centre Val de Loire (00136087)
This publication has 29 references indexed in Scilit:
- Antibody–Drug Conjugates: Future Directions in Clinical and Translational Strategies to Improve the Therapeutic IndexClinical Cancer Research, 2019
- Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methodsInternational Journal of Cancer, 2018
- Minireview: Addressing the retro-Michael instability of maleimide bioconjugatesDrug Discovery Today: Technologies, 2018
- Antibody drug conjugates for treatment of breast cancer: Novel targets and diverse approaches in ADC designPharmacology & Therapeutics, 2018
- Strategies and challenges for the next generation of antibody–drug conjugatesNature Reviews Drug Discovery, 2017
- Optimisation of the dibromomaleimide (DBM) platform for native antibody conjugation by accelerated post-conjugation hydrolysisOrganic & Biomolecular Chemistry, 2017
- Antibody–drug conjugates for cancer therapyThe Lancet Oncology, 2016
- Safety and activity of the anti-CD79B antibody–drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 studyThe Lancet Oncology, 2015
- Self-hydrolyzing maleimides improve the stability and pharmacological properties of antibody-drug conjugatesNature Biotechnology, 2014
- Contribution of Linker Stability to the Activities of Anticancer ImmunoconjugatesBioconjugate Chemistry, 2008